BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting?

Nieves Martínez Lago,A. Montes,Marta Covela Rúa,Elena Brozos Vazquez,Juan De la Cámara,Mónica Jorge Fernández,Antia Cousillas,J Mendez,Marta Carmona Campos,Carlos Romero Reinoso,Paula González Villarroel,Yolanda Vidal Insua,Elena Gallardo Martin,Begoña Graña,F. Rivera,María Luz Pellón-Augusto,Guillermo Alfonso Quintero Aldana,Margarita Reboredo López,Sonia Candamio Folgar,Mercedes Salgado Fernández

BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting?

2018

e15561Background: BRAF mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with metastatic colorectal cancer (mCRC). BRAF (V600E) mt is a strong predictor of a poor progn...

Keywords:

Pathology
BRAF V600E
Colorectal cancer
Mutant
Medicine
Cancer research
V600E
antiangiogenic therapy
Missense mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations